Thermo Fisher Scientific, the world leader in serving science, from June 22-25, will be showcasing new capabilities, strategic investments, and initiatives at the BIO International 2026 in San Diego that are helping pharma and biotech customers advance innovation, simplify complex workflows and bring therapies to patients faster.
Spanning AI-enabled research, clinical development and advanced manufacturing, these investments reinforce Thermo Fisher’s role as a trusted strategic provider of integrated solutions, helping customers simplify drug development from discovery through commercialization.
As demand grows for advanced therapies and pressure increases to reduce development timelines, biopharma companies are increasingly seeking connected, data-driven approaches to research, clinical development, and manufacturing. Thermo Fisher officials say they are striving to help customers harness AI, scientific data, and integrated development capabilities to improve productivity, enhance decision-making, and reduce complexity across the drug development lifecycle.
“AI, connected scientific data and advanced manufacturing are reshaping how therapies are discovered, developed and delivered,” said Mike Shafer, executive vice president and president, Biopharma Services, Thermo Fisher Scientific. “With our Accelerator Drug Development collaborations and integrated development ecosystem, Thermo Fisher is well-positioned to help customers translate breakthrough science into clinical and commercial success with greater confidence.”
Recent investments and innovations highlighted at BIO International 2026 include:
Pharma Services and Advanced Manufacturing
Expanded global sterile fill-finish and device assembly capacity to support prefilled syringes, vials, cartridges and autoinjectors, including an expanded collaboration with SHL Medical to offer fully integrated device assembly services at Thermo Fisher’s Ridgefield, New Jersey site.
Expanding oral solid dose (OSD) manufacturing capabilities with advanced tableting technologies, additional laboratory capacity and new packaging and serialization capabilities across global sites.
Added significant additional biologics drug substance capacity across facilities in the U.S. and Switzerland, supporting increasing demand for biologic therapies.
Launching new GMP monoclonal antibody manufacturing capabilities in Plainville, Mass., in the second half of 2026, supporting large-scale production of mAb therapies across multiple indications.
Expanded our global Bioprocess Design Center (BDC) network with new BDC facilities in the U.S. and India, complementing existing centers in China, Korea and Singapore. The centers provide customers with local expertise, advanced bioprocessing technologies, technical consulting and collaborative laboratory environments to streamline process development, improve manufacturing readiness and support successful scale-up.
Clinical Research and Data Intelligence
Expanded digital clinical research capabilities through the acquisition of Clario Holdings Inc., adding industry-leading endpoint data and evidence generation solutions that have supported approximately 70 percent of FDA and EMA novel drug approvals over the past decade, together with HealthVerity and Datavant to advance real-world evidence and trial optimization.
Expanded AI-enabled analytics and workflow solutions designed to help customers improve clinical trial efficiency, streamline interpretation of complex scientific and clinical data, and support more informed development decisions.
AI-Enabled Research and Scientific Workflows
Expanded AI-enabled scientific workflows through strategic relationships with NVIDIA, OpenAI, TetraScience and BenchSci, helping customers improve experimental design, automate laboratory workflows and generate deeper insights from complex scientific data.
Through Accelerator™ Drug Development, Thermo Fisher is helping emerging biotech companies combine scientific expertise, AI-enabled workflows, laboratory technologies and development capabilities to support a more efficient transition from discovery through clinical development.
Recent software acquisitions, MSAID and Proteinaceous, strengthen Thermo Fisher’s proteomics ecosystem by adding AI, machine learning and proteoform analysis capabilities that help scientists interpret complex population-scale datasets faster and with greater confidence.
Advanced connected laboratory capabilities designed to help customers unify scientific data across instruments, applications and research environments, enabling more scalable, automated and data-driven R&D operations.
Scientific Innovation and Enabling Technologies
Introduced new molecular and cell therapy workflow innovations, including the Applied Biosystems™ PowerFlex™ Thermal Cycler and the Gibco™ CTS™ Compleo™ Fill and Finish System, designed to help customers advance discovery through clinical translation.
Unveiled the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, an integrated platform to enable scalable cell therapy manufacturing with precise control, flexibility and regulatory readiness.
Launched Gibco™ CHOvantage™ GS Cell Line Development Kit enabling researchers to generate high-performing CHO lines that enable high productivity, streamlined timelines and royalty-free, clinical-stage licensing options to support scalable manufacturing.
Attendees can meet with Thermo Fisher experts at Booth 5125 to explore solutions spanning AI-enabled research, clinical development, biologics manufacturing, sterile fill-finish, analytical services and digital innovation.
Leaders participate in panel discussions at BIO
Thermo Fisher experts will participate in several sessions during the conference, including:
Securing America's Biomanufacturing Future: Industry Forums in Action – James Hulvat, General Manager, Bend, Ore. site, Pharma Services, Monday, June 22, 3 - 4 p.m., San Diego Convention Center, 111 Harbor Drive, San Diego CA 92101
What it Takes to Move Innovation Forward: Accelerating the Journey from Science to Patients – Fireside Chat with the Maryland Tech Council – Daniella Cramp, President, BioProduction, Tuesday, June 23, 3 p.m., Maryland Tech Council, Pavilion 4407, San Diego Convention Center, 111 Harbor Drive, San Diego, CA 92101
Beyond Federal Funding: The New Research Rescue Mission – Todd Rudo, Chief Medical Officer, Clario, Tuesday, June 23, 4:15-5:15 p.m., San Diego Convention Center, 111 Harbor Drive, San Diego CA 92101
Bioprocessing topic – Advancing Monoclonal Antibody Manufacturing Through Integrated Process Intensification - Adam Goldstein, Sr. Director R&D, BioProduction Wednesday, June 24, 10-10:20 a.m., BPI Theater, Bioprocessing Zone, San Diego Convention Center, 111 Harbor Drive, San Diego CA 92101
About Thermo Fisher Scientific Florence, South Carolina East
The Thermo Fisher Scientific Florence, SC (East) site is a flexible drug substance manufacturing site offering highly potent compound handling, process development and scale up and large-scale and mid-scale API production. The site, located at 6173 East Old Marion Highway, also has capabilities in solid state chemistry, spray drying, and micronization. The facility is fully compliant with all applicable regulations and meets the most stringent production, quality, cGMP (current Good Manufacturing Practices), safety and environmental standards.
Comments
No comments on this item Please log in to comment by clicking here